Search Results - "INGERSLEV, J."

Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: results from the European Network of Rare Bleeding Disorders by PEYVANDI, F., PALLA, R., MENEGATTI, M., SIBONI, S. M., HALIMEH, S., FAESER, B., PERGANTOU, H., PLATOKOUKI, H., GIANGRANDE, P., PEERLINCK, K., CELKAN, T., OZDEMIR, N., BIDLINGMAIER, C., INGERSLEV, J., GIANSILY‐BLAIZOT, M., SCHVED, J. F., GILMORE, R., GADISSEUR, A., BENEDIK‐DOLNIČAR, M., KITANOVSKI, L., MIKOVIC, D., MUSALLAM, K. M., ROSENDAAL, F. R.

“…Background:  The European Network of Rare Bleeding Disorders (EN‐RBD) was established to bridge the gap between knowledge and practise in the care of patients…”
Get full text

Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor by SADLER, J. E., BUDDE, U., EIKENBOOM, J. C. J., FAVALORO, E. J., HILL, F. G. H., HOLMBERG, L., INGERSLEV, J., LEE, C. A., LILLICRAP, D., MANNUCCI, P. M., MAZURIER, C., MEYER, D., NICHOLS, W. L., NISHINO, M., PEAKE, I. R., RODEGHIERO, F., SCHNEPPENHEIM, R., RUGGERI, Z. M., SRIVASTAVA, A., MONTGOMERY, R. R., FEDERICI, A. B.

“…von Willebrand disease (VWD) is a bleeding disorder caused by inherited defects in the concentration, structure, or function of von Willebrand factor (VWF)…”
Get full text

Whole blood clot formation phenotypes in hemophilia A and rare coagulation disorders. Patterns of response to recombinant factor VIIa by Sørensen, B., Ingerslev, J.

“…Until now, no routinely used clotting assay has demonstrated the power to reflect significantly a patient's response to recombinant factor (rF)VIIa. Adopting a…”
Get full text

Virtual surgical analysis: long-term cone beam computed tomography stability assessment of segmental bimaxillary surgery by Holte, M.B., Diaconu, A., Ingerslev, J., Thorn, J.J., Pinholt, E.M.

“…The assessment of the stability of orthognathic surgery is often time-consuming, relies on manual re-identification of anatomical landmarks, and has been based…”
Get full text

Standardization of thromboelastography: a report from the TEG-ROTEM working group by CHITLUR, M., SORENSEN, B., RIVARD, G. E., YOUNG, G., INGERSLEV, J., OTHMAN, M., NUGENT, D., KENET, G., ESCOBAR, M., LUSHER, J.

“…Laboratory evaluation of bleeding disorders has been performed with the standard clotting assays such as the PT and PTT for several decades. Our improved…”
Get full text

Fibrinogen concentrate substitution therapy in patients with massive haemorrhage and low plasma fibrinogen concentrations by Fenger-Eriksen, C., Lindberg-Larsen, M., Christensen, A.Q., Ingerslev, J., Sørensen, B.

“…Patients experiencing massive haemorrhage are at high risk of developing coagulopathy through loss, consumption, and dilution of coagulation factors and…”
Get full text

A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM‐1 VWD) by TOSETTO, A., RODEGHIERO, F., CASTAMAN, G., GOODEVE, A., FEDERICI, A. B., BATLLE, J., MEYER, D., FRESSINAUD, E., MAZURIER, C., GOUDEMAND, J., EIKENBOOM, J., SCHNEPPENHEIM, R., BUDDE, U., INGERSLEV, J., VORLOVA, Z., HABART, D., HOLMBERG, L., LETHAGEN, S., PASI, J., HILL, F., PEAKE, I.

“…Background: A quantitative description of bleeding symptoms in type 1 von Willebrand disease (VWD) has never been reported. Objectives: The aim was to…”
Get full text

Whole blood coagulation thrombelastographic profiles employing minimal tissue factor activation by Sørensen, B., Johansen, P., Christiansen, K., Woelke, M., Ingerslev, J.

“…We investigated whole blood coagulation by thrombelastography (TEG) employing activation with minute amounts of tissue factor (TF). Continuous raw data…”
Get full text

Mechanisms of hydroxyethyl starch‐induced dilutional coagulopathy by FENGER‐ERIKSEN, C., TØNNESEN, E., INGERSLEV, J., SØRENSEN, B.

“…Background: The biochemical mechanisms causing dilutional coagulopathy following infusion of hydroxyethyl starch 130/0.4 (HES) are not known in detail…”
Get full text

Fibrinogen substitution improves whole blood clot firmness after dilution with hydroxyethyl starch in bleeding patients undergoing radical cystectomy: a randomized, placebo‐controlled clinical trial by FENGER‐ERIKSEN, C., JENSEN, T. M., KRISTENSEN, B. S., JENSEN, K. M., TØNNESEN, E., INGERSLEV, J., SØRENSEN, B.

“…Background: Infusion of artificial colloids such as hydroxyethyl starch (HES) induces coagulopathy to a greater extent than simple dilution. Several studies…”
Get full text

Autotransplantation of premolars: does surgeon experience matter? by Jakobsen, C., Stokbro, K., Kier-Swiatecka, E., Ingerslev, J., Thorn, J.J.

“…Autotransplantation of premolars is a well-established method to rehabilitate aplasia of premolars. Nevertheless, with the introduction of titanium implants,…”
Get full text

Stressful life events are associated with a poor in-vitro fertilization (IVF) outcome: a prospective study by Ebbesen, S.M.S., Zachariae, R., Mehlsen, M.Y., Thomsen, D., Højgaard, A., Ottosen, L., Petersen, T., Ingerslev, H.J.

“…BACKGROUND There is preliminary evidence to suggest an impact of stress on chances of achieving a pregnancy with in-vitro fertilization (IVF). The majority of…”
Get full text

European principles of haemophilia care by COLVIN, B. T., ASTERMARK, J., FISCHER, K., GRINGERI, A., LASSILA, R., SCHRAMM, W., THOMAS, A., INGERSLEV, J.

“…As the management of haemophilia is complex, it is essential that those with the disorder should have ready access to a range of services provided by a…”
Get full text

Tailoring haemostatic treatment to patient requirements - an update on monitoring haemostatic response using thrombelastography by SØRENSEN, B., INGERSLEV, J.

“…Currently, there is no single haemostasis laboratory test that has the capacity to accurately illustrate the clinical effects of procoagulant or anticoagulant…”
Get full text

Endothelial dysfunction, increased inflammation, and activated coagulation in HIV‐infected patients improve after initiation of highly active antiretroviral therapy by Arildsen, H, Sørensen, KE, Ingerslev, JM, Østergaard, LJ, Laursen, AL

“…Objectives Endothelial dysfunction and inflammation have been demonstrated to be markers of cardiovascular risk. We investigated the effects of HIV infection…”
Get full text

Dynamic APTT parameters: applications in thrombophilia by SØRENSEN, B., INGERSLEV, J.

“…Background: Patients with a history of venous thrombosis occasionally have shortened APTTs when compared with those of healthy references, but the clinical…”
Get full text

Time-lapse monitoring as a tool for clinical embryo assessment by Kirkegaard, Kirstine, Agerholm, Inge E., Ingerslev, Hans Jakob

“…As elective transfer of a single embryo (eSET) becomes increasingly accepted, the need to improve implantation rates becomes crucial. Selecting the most…”
Get full text

IVF and stillbirth: a prospective follow-up study by Wisborg, K., Ingerslev, H.J., Henriksen, T.B.

“…BACKGROUND Previous studies have indicated that the risk of stillbirth is increased in singleton pregnancies achieved after assisted reproduction technology…”
Get full text

Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis by White, 2nd, G C, Rosendaal, F, Aledort, L M, Lusher, J M, Rothschild, C, Ingerslev, J

Get more information

Prophylaxis in congenital factor VII deficiency: indications, efficacy and safety. Results from the Seven Treatment Evaluation Registry (STER) by Napolitano, Mariasanta, Giansily-Blaizot, Muriel, Dolce, Alberto, Schved, Jean F, Auerswald, Guenter, Ingerslev, Jørgen, Bjerre, Jens, Altisent, Carmen, Charoenkwan, Pimlak, Michaels, Lisa, Chuansumrit, Ampaiwan, Di Minno, Giovanni, Caliskan, Umran, Mariani, Guglielmo

“…Because of the very short half-life of factor VII, prophylaxis in factor VII deficiency is considered a difficult endeavor. The clinical efficacy and safety of…”
Get full text